Mike Hayes CBE
Areas of Expertise
Planning policy, Urban design, Urban regeneration
Mike is an urban planner and former public sector senior officer, with extensive experience of spatial planning, design, regeneration, and development at both strategic and local levels.
Mike’s career includes Director of Planning in Liverpool and Glasgow; delivering regeneration programmes in the heart of London; re-engineering the spatial vision of smaller communities; playing a lead role in delivering flagship development and infrastructure projects; and leading a development agency working across three diverse towns being prepared for major expansion. Since 2010, as an independent consultant, he has worked for private clients, examined major infrastructure projects for the Planning Inspectorate, taken part in and chaired many design reviews.
He was secretary of the National Planning Forum for eight years, is an appointed High Street Expert and member of Historic England’s Historic Places Panel. In 2004 he was President of the Royal Town Planning Institute; is an Honorary Fellow of the Royal Institute of British Architects and was appointed Commander of the British Empire for services to local government and the voluntary sector in 2008; he is a member of the Academy of Urbanism and in 2018 was awarded Fellow of the Academy of Social Sciences.
Great post and right to the point. I don’t know if this is truly the best place
to ask but do you folks have any thoughts on where
to employ some professional writers? Thanks 🙂 Escape room lista
I like this weblog very much, Its a very nice position to read and get
information..
amazon priligy Some researchers believe that one possible cause of triple negative breast cancer is a faulty BRCA1 gene
priligy tablets Don t be tempted into taking the full Dbol dosage before a workout
where buy cheap cytotec for sale The Swedish meta analysis resolved these questions appropriately
how can i get cheap cytotec pill 95 Unlike in TriCor and Suboxone, in which the defendants fully removed the older formulation from the market, the Namenda I defendants planned to continue making the older formulation available to any patient who had a medical need for it